Janssen Search
Search results
Pushing Back the Threat of Influenza
Pushing Back the Threat of Influenza: Reflecting on the WHO Global Influenza Strategy The publication of the World Health Organization (WHO)’s new Global Influenza Strategy gives us pause to reflect on where we currently stand in the fight against ...
Building Equitable Access For Patients With Lung Cancer
Building Equitable Access to Next-Generation Sequencing and Targeted Therapies for All Patients With Lung Cancer The cancer research landscape looked vastly different when I began my career almost 15 years ago. As just one example, when I graduated from ...
Janssen Receives Positive CHMP Opinions for Novel Bispecific Antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Jul 21, 2023 Belgium Talquetamab is the first therapy targeting GPRC5D to receive a positive CHMP Opinion Teclistamab, the first BCMA-targeting bispecific antibody to be approved in Europe, receives positive CHMP Opinion for reduced, biweekly dosing ...
Johnson & Johnson highlights its preeminent leadership in hematology through differentiated blood cancer portfolio and pipeline with new clinical and real-world data at ASH
Nov 29, 2023 United States Data highlights strength of multi-target, multi-platform multiple myeloma portfolio and continued innovation in B-cell malignancies to transform patient outcomes RARITAN, N.J., November 29, 2023 – Johnson & Johnson ...
Earth Day 2017
Why Janssen Cares About the Environment April 22, 2017 will mark the 47th annual celebration of Earth Day. To recognize Earth Day 2017, we sat down with Philip Dahlin, Global Director, Sustainability, at Janssen to learn more about the efforts of ...
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
Sep 19, 2024 United States Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT ® this year, with four indications overall RARITAN, New Jersey (September 19, 2024) – Johnson ...
Taking action together to tackle TB
Taking Action Together to Tackle TB A week is a long time in politics, so the saying goes. In that case, 135 years must be an eternity in healthcare. On March 24, 1882, German physician Robert Koch presented a paper at a medical conference which ...
European Commission Approves TALVEY®▼ (talquetamab), Janssen’s Novel Bispecific Therapy for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Aug 22, 2023 Belgium Talquetamab, the first bispecific antibody targeting GPRC5D, showed an overall response rate of more than 70 percent with durable responses, including responses achieved by over 60 percent of patients with prior T-cell redirection ...
Clinical Trial Diversity
Clinical Trial Diversity: Putting Thought to Action to Develop Sustainable Improvements The lack of diversity in clinical trials has been recognized as a major impediment to healthcare equality for decades. Unfortunately, attempts to increase ...
Empowering Black Americans for Greater Clinical Trial Representation
Empowering Black Americans for Greater Clinical Trial Representation In honor of Black History Month, Janssen is spotlighting its commitment to increase diversity among its clinical trial participants, and to expand community engagement to build ...